On June 1, Health 160 (02656.HK) fell 5.86% in regular trading, trading at 14.93 HKD/share, with trading volume of 46.85 million HKD. The stock has now extended its multi-session decline, having previously dropped 5.03% on May 26 and 5.55% on May 27.

The continued selling pressure follows a period of extreme volatility. Earlier in May, the stock surged nearly 44% in a single session with over 2.4 billion HKD in turnover after its inclusion in Stock Connect. Market participants have since engaged in aggressive profit-taking. Analysts note that the upcoming lock-up expiry window, the company's still-negative earnings (P/E at -66.12), and low gross margins in its pharmaceutical e-commerce segment remain key headwinds during its transition from concept stage to earnings delivery.

Within the Health Care Distributors sector, peers were mixed: SH PHARMA up 1.67%, BAIYUNSHAN PH up 0.39%, GUANZE MEDICAL up 0.23%, SINOPHARM down 0.06%, and YSB down 3.12%, indicating Health 160's decline is largely stock-specific rather than sector-driven.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)